Mostrando 10 resultados de: 20
Filtros aplicados
Publisher
Clinical Pharmacology and Therapeutics(3)
European Journal of Clinical Pharmacology(2)
Acta Psychiatrica Scandinavica(1)
Anales de Medicina Interna(1)
British Journal of Clinical Pharmacology(1)
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
ArticleAbstract: In a previous study we showed that the disposition of clozapine after a single oral dose is unrelatePalabras claves:Autores:Adrián LLerena, Alm C., Benitez Rodriguez J., Bertilsson L., Bondesson U., Carrillo J., Dahl M.L., Lindstrom L., Ramos S., Rodriguez de la Rubia I.Fuentes:scopusAssessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis
ArticleAbstract: From a sample of 149 unrelated Spaniards, individuals were phenotyped for their ability to hydroxylaPalabras claves:Autores:Adrián LLerena, Avram M., Benitez Rodriguez J., Cobaleda J., Gibbons R., Henthorn T., Krejcie T., Martinez C.Fuentes:scopusDEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquin oxidation polymorphism in a Spanish population
ArticleAbstract: The capacity for debrisoquin metabolism was determined in 377 healthy Spanish volunteers by measurinPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquine oxidation in schizophrenic patients treated with neuroleptics
ArticleAbstract:Palabras claves:debrisoquine, Neuroleptics, OXIDATION, SchizophreniaAutores:Adrián LLerena, Benitez Rodriguez J., Buemi A.L., Caputi A.P., Cobaleda J., García M.A., Piña B., Spina E.Fuentes:scopusDebrisoquine oxidation phenotype in psychiatric patients.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., García M.A., Martínez C., Piñas B.Fuentes:scopusAcetylator polymorphism in Parkinson's disease
ArticleAbstract: Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disePalabras claves:acetylator phenotype, debrisoquine oxidation, drug polymorphism, Parkinsonism, sulphamethazineAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Fernandez-Gundin M.J., Jimenez F.J., Ladero J.M., Martinez C., Muñoz J.J.Fuentes:scopusFrequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations
ArticleAbstract: We have investigated the prevalence of poor metabolisers (PM) of S-mephenytoin in 373 unrelated, heaPalabras claves:caucasian, drug metabolism, Mephenytoin, pharmacogenetics, Phenotype, polymorphismAutores:Adrián LLerena, Benitez Rodriguez J., Bertilsson L., Carrillo J.A., Reviriego J., Valdivielso M.J.Fuentes:scopusMolecular heterogeneity at the CYP2D gene locus in Nicaraguans: Impact of gene-flow from Europe
ArticleAbstract:Palabras claves:CYP2D, Cytochrome p450, Gene-flow, Hispanics, NicaraguansAutores:Adrián LLerena, Agúndez J.A.G., Benitez Rodriguez J., Hernandez M., Ramirez R.Fuentes:scopusOxidative polymorphism of debrisoquine in Parkinson's disease
ArticleAbstract: Oxidative phenotype and metabolic ratio (MR) of debrisoquine (DBQ) have been determined in 87 patienPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Jimenez-Jimenez F.J., Ladero J.M., Martínez C., Muñoz J.J., Puerto A.M., Valdivielso M.J.Fuentes:scopus